| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
We tried to clarify the gastrointestinal NEC (GI-NEC) pathogenesis through the DLL3 functions in this project. DLL3 has attracted interest as a novel molecular target in neuroendocrine carcinoma of the lung. Our results showed that DLL3 expression was extremely increased in the GI-NEC. Also, the knockdown of DLL3 suppressed the growth through the induction of apoptosis in GI-NEC cells. These findings suggested that DLL3 is one of the crucial molecules in GI-NEC. However, the development of the existing DLL3antibody-drug conjugate was suspended because of not overcoming standard treatment.
Hence, we conducted the establishment of a screening assay to extract the novel compound targeting DLL3.
|
